Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis

Photodermatology Photoimmunology and Photomedicine

Volumn 28, Issue 5, 2012, Pages 250-257

  Knobler, Robert ^a   Duvic, Madeleine ^b   Querfeld, Christiane ^c,d   Straus, David ^d   Horwitz, Steven ^d   Zain, Jasmine ^d   Foss, Francine ^e   Kuzel, Timothy ^c   Campbell, Kim ^f   Geskin, Larisa ^g  

^a Universitatsklinik fur Dermatologie   (Austria)

^b University of Texas Health Science Center at Houston   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d College of Physicians and Surgeons ^*  (United States)

^e YALE CANCER CENTER   (United States)

^f Therakos Inc   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical observations; Cutaneous T cell lymphoma; Interventions and therapeutic trials; Photopheresis

Indexed keywords

METHOXSALEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CUTANEOUS T CELL LYMPHOMA; DRUG BLOOD LEVEL; ERYTHRODERMA; EXTRACORPOREAL PHOTOPHERESIS; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PUVA; RETROSPECTIVE STUDY; SEZARY CELL; SKIN FUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CLASSIFICATION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PHOTOPHERESIS; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 84866184699     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2012.00689.x     Document Type: Article

References (39)

1. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18: 2908-2925.
2. Väkevä L, Pukkala E, Ranki A. Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma. J Invest Dermatol 2000; 115: 62-65.
3. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007; 143: 854-859.
4. Willemze R, Dreyling M, ESMO Guidelines Working Group. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): 115-118.
5. Olsen E, Vonderheid E, Pimpinelli N etal. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
6. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12 (Suppl. 2): 7-12.
7. Gatza E, Rogers CE, Clouthier SG etal. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112: 1515-1521.
8. Rao V, Saunes M, Jørstad S, Moen T. Cutaneous T cell lymphoma and graft-versus-host disease: a comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3+ regulatory T cells. Clin Immunol 2009; 133: 303-313.
9. Gjerdrum LM, Woetmann A, Odum N etal. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007; 21: 2512-2518.
10. Edelson R, Berger C, Gasparro F etal. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987; 316: 297-303.
11. Duvic M. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16: 1111-1120.
12. Olsen E, Duvic M, Frankel A etal. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-388.
13. Duvic M, Hymes K, Heald P etal. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471.
14. Gottlieb SL, Wolfe JT, Fox FE etal. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996; 35: 946-957.
15. Prinz B, Behrens W, Hölzle E, Plewig G. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma - the Düsseldorf and Munich experience. Arch Dermatol Res 1995; 287: 621-626.
16. Talpur R, Demierre MF, Geskin L etal. Multicenter photopheresis intervention trial in early stage mycosis fungoides. Clin Lymphoma Myeloma Leuk 2011; 11: 219-227.
17. Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003; 16: 337-346.
18. Vonderheid EC, Bernengo MG. The Sézary syndrome: hematologic criteria. Hematol Oncol Clin North Am 2003; 17: 1367-1389. viii. Review.
19. Olsen EA, Whittaker S, Kim YH etal. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29: 2598-2607.
20. Kashani-Sabet M, McMillan A, Zackheim HS. A modified staging classification for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001; 45: 700-706.
21. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-866.
22. Macheiner W, Jantschitsch C, Graninger W etal. Sézary syndrome and seronegative polyarthritis: treatment with extracorporeal photochemotherapy. J Am Acad Dermatol 2003; 48: 220-226.
23. Assaf C, Hummel M, Zemlin M etal. Transition of Sézary syndrome into mycosis fungoides after complete clinical and molecular remission under extracorporeal photophoresis. J Clin Pathol 2004; 57: 1325-1328.
24. Maeda A, Schwarz A, Kernebeck K etal. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol 2005; 174: 5968-5976.
25. Lamioni A, Parisi F, Isacchi G etal. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005; 79: 846-850.
26. Kim EJ, Hess S, Richardson SK etal. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 798-812.
27. Albert ML. Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 2004; 4: 223-231.
28. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2: 965-975.
29. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191: 411-416.
30. Girardi M, Edelson RL. Cutaneous T-cell lymphoma: pathogenesis and treatment. Oncology (Williston Park) 2000; 14: 1061-1070.
31. Wong HK. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma). G Ital Dermatol Venereol 2008; 143: 375-383.
32. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247-1252.
33. Suchin KC, Gottleib SL, Wolfe JT, DeNardo BJ etal. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy. Arch Dermatol 2002; 138: 1054-1060.
34. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 2009; 48: 243-252.
35. Miller JD, Kirkland EB, Domingo DS etal. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 2007; 23: 163-171.
36. Zic JA, Stricklin GP, Greer JP etal. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35: 935-945.
37. Vonderheid EC, Zhang Q, Lessin SR etal. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38: 207-220.
38. Agar NS, Wedgeworth E, Crichton S etal. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730-4739.
39. Geskin L. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma. Skin Therapy Lett 2007; 12: 1-4.